MerLion Pharmaceuticals Pte. Ltd.
www.merlionpharma.com
Latest From MerLion Pharmaceuticals Pte. Ltd.
Antibiotics Pipeline Is Lively, But Sponsors Are Fragile
Regulatory uncertainty could imperil the crop of emerging companies making a go of it in the incentive-laden US anti-infective space.
Break-Point: FDA Committee Votes To Restrict Quinolones, But Does Not Endorse Disability Syndrome
An FDA advisory committee review of quinolone antibiotic safety focused on a very old safety issue – but points to a new era in antibiotic development, and restricted use models.
MerLion Preps Finafloxacin For Phase III As Advantages Confirmed
Singapore-based MerLion is planning to take its lead development project, the antibiotic finafloxacin, into a Phase III program for urinary tract infections after Phase II results showed advantages over the current standard of care ciprofloxacin, along with rapid, broad activity and potential for the easy switching of patients from intravenous to oral dosing.
ICAAC 2015: Scrip Connects With Cidara, MerLion And Paratek
Scrip caught up with several biopharma executives on Sept. 18 during the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) in San Diego to discuss the status of their anti-infective drug development programs.
Company Information
- Industry
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Infectious & Viral Diseases
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Asia
-
Southeast Asia
-
Singapore
-
Singapore
-
Southeast Asia
-
Asia
- Parent & Subsidiaries
- MerLion Pharmaceuticals Pte. Ltd.
- Senior Management
-
Tony Buss, PhD, Pres. & CEO
David Dally, CFO
Martin Everett, PhD, Head, Research - Contact Info
-
MerLion Pharmaceuticals Pte. Ltd.
Phone: (65) 6829 5600
1 Science Park Rd., The Capricorn #05-01
, 117528
Singapore
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice